Tracy McCarty
Head of Investor Relations
Replay available
BioMarin Pharmaceutical Inc. (BMRN) Q1 2026 Earnings Call
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) Q1 2026 earnings conference call, held 2026-05-04. Replay captured from the company's public earnings webcast.
Hosted by
Featured presenters
Alexander Hardy
President and Chief Executive Officer
Brian Mueller
Chief Financial Officer
Kristen Hubbard
Chief Commercial Officer
Greg Freiberg
Chief R&D Officer
Paul Matisse
Analyst, Stiefel
Phil Nadal
Analyst, TD Callen
Chris Raymond
Analyst, Raymond James
Investor webinar replay
Watch the replay and follow the connected company analysis, news, and investor updates for Biomarin Pharmaceutical Inc..
Replay transcript excerpt
WEBVTT 00:00:00.031 -- 00:00:05.018 Good afternoon and welcome everyone to the Biomarin Pharmaceutical First Quarter 2026 00:00:05.018 -- 00:00:08.703 conference call. Today's conference is being recorded. 00:00:08.703 -- 00:00:11.888 All lines have been placed on mute to prevent any background noise. 00:00:11.888 -- 00:00:15.213 After the speaker's remarks, there will be a question and answer session. 00:00:15.213 -- 00:00:19.098 If you would like to ask a question during this time, simply press the star key, followed 00:00:19.098 -- 00:00:21.722 by the number one on your telephone keypad. 00:00:21.722 -- 00:00:24.165 If you would like to withdraw your question, press star one again. 00:00:24.165 -- 00:00:29.052 At this time, I would like to turn the conference over to Tracy McCarty, Head of Investor 00:00:29.052 -- 00:00:32.321 Relations. Please go ahead. 00:00:32.564 -- 00:00:37.091 Thank you, operator. To remind you, this non-confidential presentation contains forward-looking 00:00:37.091 -- 00:00:42.419 statements about the business prospects of Biomarin Pharmaceutical Inc., including expectations 00:00:42.419 -- 00:00:46.605 regarding Biomarin's financial performance, commercial products, and potential future 00:00:46.605 -- 00:00:50.351 products in different areas of therapeutic research and development. 00:00:50.351 -- 00:00:55.098 Results may differ materially depending on the progress of Biomarin's product programs, 00:00:55.098 -- 00:01:00.305 actions of regulatory authorities, availability of capital, future actions in the pharmaceutical 00:01:00.305 -- 00:01:05.411 market, and developments by competitors. And those factors detailed in Biomarin's filings 00:01:05.411 -- 00:01:11.238 with the Securities and Exchange Commission, such as 10Q, 10K, and 8K rep...